All In Biotech

Drug Trial Radar · NCT07855276

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

A Randomized, Double-blind, Placebo-controlled Mechanistic Study in Adult Patients With Moderate to Severe Hidradenitis Suppurativa to Explore the Effects of Remibrutinib on Tissue Level

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 29, 2026

Primary completion

Nov 29, 2027

Study completion Dec 27, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • LOU064Drug

    Remibrutinib

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fold change from baseline in auto-antibodiesTime frame: Baseline, Week 16

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Clinical Trials

    San Diego, California · Recruiting

  • Apex Clinical Research Center LLC

    Mayfield Heights, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.